EVAX Stock Overview
Evaxion Biotech A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Evaxion A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.74 |
| 52 Week High | US$20.81 |
| 52 Week Low | US$1.20 |
| Beta | -0.23 |
| 1 Month Change | 33.03% |
| 3 Month Change | -30.06% |
| 1 Year Change | -90.64% |
| 3 Year Change | -98.13% |
| 5 Year Change | n/a |
| Change since IPO | -99.65% |
Recent News & Updates
Recent updates
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Shareholder Returns
| EVAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 16.9% | 3.7% | 5.3% |
| 1Y | -90.6% | -14.2% | 11.9% |
Return vs Industry: EVAX underperformed the US Biotechs industry which returned -14.2% over the past year.
Return vs Market: EVAX underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| EVAX volatility | |
|---|---|
| EVAX Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: EVAX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EVAX's weekly volatility has decreased from 19% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 46 | Christian Kanstrup | evaxion.ai |
Evaxion Biotech A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus.
Evaxion A/S Fundamentals Summary
| EVAX fundamental statistics | |
|---|---|
| Market cap | US$11.00m |
| Earnings (TTM) | -US$10.57m |
| Revenue (TTM) | US$3.34m |
3.3x
P/S Ratio-1.0x
P/E RatioIs EVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVAX income statement (TTM) | |
|---|---|
| Revenue | US$3.34m |
| Cost of Revenue | US$0 |
| Gross Profit | US$3.34m |
| Other Expenses | US$13.91m |
| Earnings | -US$10.57m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.67 |
| Gross Margin | 100.00% |
| Net Profit Margin | -316.00% |
| Debt/Equity Ratio | -494.4% |
How did EVAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/17 05:14 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evaxion A/S is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Thomas Flaten | Lake Street Capital Markets, LLC |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |